The Road to Bioabsorbable Stents: Reaching Clinical Reality?

[1]  Bernd Heublein,et al.  Preliminary Results after Application of Absorbable Metal Stents in Patients with Critical Limb Ischemia , 2005, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[2]  M. Hofmann,et al.  Endovascular interventions in iliac and infrainguinal occlusive artery disease. , 2004, Journal of interventional cardiology.

[3]  N. Krott,et al.  Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. , 2004, European heart journal.

[4]  P. Serruys,et al.  CORONARY ARTERY DISEASE Original Studies Clinical Outcomes for Sirolimus-Eluting Stent Implantation and Vascular Brachytherapy for the Treatment of In-Stent Restenosis , 2004 .

[5]  R. Beyar.  Novel Approaches to Reduce Restenosis , 2004, Annals of the New York Academy of Sciences.

[6]  P. Serruys,et al.  Classification and Current Treatment Options of In-Stent Restenosis , 2004, Herz.

[7]  V. Rajagopal,et al.  Coronary restenosis: a review of mechanisms and management. , 2003, The American journal of medicine.

[8]  A Haverich,et al.  Left main coronary artery fistula exiting into the right atrium , 2003, Heart.

[9]  S. Apisarnthanarax,et al.  Intravascular Brachytherapy: A Review of the Current Vascular Biology , 2003, American journal of clinical oncology.

[10]  Ciro Indolfi,et al.  Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. , 2003, Trends in cardiovascular medicine.

[11]  P. Doriot,et al.  A morphological-mechanical explanation of edge restenosis in lesions treated with vascular brachytherapy. , 2003, Cardiovascular radiation medicine.

[12]  M. Bennett,et al.  IN-STENT STENOSIS: PATHOLOGY AND IMPLICATIONS FOR THE DEVELOPMENT OF DRUG ELUTING STENTS , 2003, Heart.

[13]  J. Palmaz,et al.  Influence of stent design and material composition on procedure outcome. , 2002, Journal of vascular surgery.

[14]  Levon M Khachigian,et al.  Coronary In-stent Restenosis: Current Status and Future Strategies , 2022 .

[15]  M. Peuster,et al.  A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal—results 6–18 months after implantation into New Zealand white rabbits , 2001, Heart.

[16]  E Regar,et al.  Stent development and local drug delivery. , 2001, British medical bulletin.

[17]  A. Lansky,et al.  Intracoronary radiation with gamma wire inhibits recurrent in-stent restenosis. , 2001, Cardiovascular radiation medicine.

[18]  A. Colombo,et al.  Biodegradable stents : "fulfilling the mission and stepping away". , 2000, Circulation.

[19]  H. Uehata,et al.  Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.

[20]  R. Virmani,et al.  Pathology of in-stent restenosis. , 1999, Current opinion in lipidology.

[21]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[22]  P. Serruys,et al.  Late coronary occlusion after intracoronary brachytherapy. , 1999, Circulation.

[23]  R. Waksman,et al.  Late thrombosis after radiation. Sitting on a time bomb. , 1999, Circulation.

[24]  RonWaksman.  Late Thrombosis After Radiation , 1999 .

[25]  Eric J. Topol,et al.  Textbook of Interventional Cardiology , 1999 .

[26]  J. Mayer,et al.  Biomaterialien – humane Toleranz und Integration , 1999, Der Chirurg.

[27]  H Shimokawa,et al.  Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. , 1998, Journal of the American College of Cardiology.

[28]  Antonio Colombo,et al.  Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.

[29]  Mark N. Gomez.  Magnesium and Cardiovascular Disease , 1998, Anesthesiology.

[30]  K. Seung,et al.  Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. , 1997, Circulation.

[31]  E J Topol,et al.  Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. , 1997, Journal of the American College of Cardiology.

[32]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[33]  A. Colombo,et al.  Results of coronary stenting for restenosis. , 1996, Journal of the American College of Cardiology.

[34]  M. Leon,et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.

[35]  M. Leon,et al.  Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. , 1996, Circulation.

[36]  A. Colombo,et al.  A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. , 1996, Circulation.

[37]  M. Labinaz,et al.  Biodegradable stents: the future of interventional cardiology? , 1995, Journal of interventional cardiology.

[38]  P Hall,et al.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. , 1995, Circulation.

[39]  J. Tanguay,et al.  Current status of biodegradable stents. , 1994, Cardiology clinics.

[40]  J. Badger,et al.  Medical emergencies during cardiac rehabilitation: a naturalistic inquiry of the psychologic impact on peers. , 1994, The Journal of cardiovascular nursing.

[41]  S. Goldberg,et al.  Intracoronary ultrasound observations during stent implantation. , 1994, Circulation.

[42]  L. Lemberg,et al.  The importance of magnesium in cardiovascular disease. , 1993, American Journal of Critical Care.

[43]  J. Vitale.  Magnesium deficiency and cardiovascular disease , 1992, The Lancet.

[44]  W. Ferrando.  Review of corrosion and corrosion control of magnesium alloys and composites , 1989 .

[45]  J C Greenfield,et al.  Interventional cardiac catheterization at Duke Medical Center. , 1988, The American journal of cardiology.

[46]  F Joffre,et al.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.

[47]  P. Erne,et al.  Vasopressin-induced activation of human blood platelets: prominent role of Mg2+ , 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

[48]  A. Grüntzig,et al.  [The percutaneous dilatation of chronic coronary stenoses--experiments and morphology]. , 1977, Schweizerische medizinische Wochenschrift.

[49]  O. Lurmann,et al.  [Therapeutic use of magnesium]. , 1951, Medizinische Klinik.

[50]  J. Tobis,et al.  The challenge of in-stent restenosis: insights from intravascular ultrasound. , 2003, European heart journal.

[51]  Stühlinger H-G,et al.  Magnesium in Cardiovascular Disease , 2002 .

[52]  A Machraoui,et al.  Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. , 2000, Journal of the American College of Cardiology.

[53]  E. Wintermantel,et al.  [Biomaterials, human tolerance and integration]. , 1999, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[54]  H Sack,et al.  [Catheter-based radiotherapy to inhibit restenosis after coronary stenting]. , 1998, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[55]  J. Palmaz.  New advances in endovascular technology. , 1997, Texas Heart Institute journal.

[56]  S. Kayser,et al.  The role of magnesium in cardiovascular disease. , 1994, Progress in Cardiovascular Nursing.

[57]  M. Arsenian.  Magnesium and cardiovascular disease. , 1993, Progress in cardiovascular diseases.

[58]  B. Altura,et al.  Cardiovascular risk factors and magnesium: relationships to atherosclerosis, ischemic heart disease and hypertension. , 1991, Magnesium and trace elements.